Analyst: This Drug Stock Could Quintuple

Gun stocks initially rallied today, but RGR has reversed lower

Managing Editor
Nov 6, 2017 at 2:58 PM
facebook twitter linkedin


Stocks are trading higher this afternoon, with traders digesting major M&A developments and high-profile Saudi Arabian arrests. Among the stocks making big moves this afternoon are luxury retailer Michael Kors Holdings Ltd (NYSE:KORS), firearm producer Sturm Ruger & Company Inc (NYSE:RGR), and woman's healthcare company TherapeuticsMD Inc (NASDAQ:TXMD). Here's a quick look at what's moving shares of KORS, RGR, and TXMD.

KORS Hits New High After Earnings Beat, Guidance

Michael Kors stock is up 15.2% at $54.87, and earlier touched a fresh annual high of $55, after the luxury retailer reported a fiscal second-quarter earnings beat and raised its full-year sales forecast. As a result, Jefferies raised its price target on KORS stock to $62 from $60.

Options traders have been put-heavy towards KORS recently, with data from the International Securities Exchange (ISE), Chicago Board Options Exchange (CBOE), and NASDAQ OMX PHLX (PHLX) showing its 10-day put/call volume ratio at 2.71. Ranking in the 93rd percentile of its annual range, this high ratio suggests that puts have been bought to open over calls at a faster-than-usual clip during the past two weeks.

Gun Stocks Reverse Early Gains

Shares of RGR spent the majority of the morning higher, but at last check were 1.7% lower at $49.95. Gun stocks initially ticked higher following Sunday's mass shooting in rural Texas that killed 26, as some traders expect a run on firearms before possible gun-control legislation can be introduced. RGR stock is down 5.2% year-to-date, with recent rebound attempts stalling in the face of its 200-day moving average and the key $55 area.

A few short sellers could be breathing a sigh of relief after RGR stock reversed early gains. Short interest represents more than 24% of Sturm Ruger stock's total available float, or just under three weeks' worth of pent-up buying demand, at the security's average daily trading volume.

TXMD Stock Skyrockets on 'Most Important Event in the Company's History'

TXMD stock is skyrocketing, after the company reported a narrower-than-expected third-quarter loss and said it plans to resubmit a marketing application for its TX-004HR drug. "The ability to resubmit the TX-004 NDA without the need for 12-month endometrial safety data is, perhaps, the most important event in the company's history," said Cantor Fitzgerald, which has an "overweight" rating and $32 price target on TXMD -- more than five times the stock's current price. The stock was last seen 35.3% higher to trade at $5.90, in territory not touched since mid-September.

Short interest on TXMD has fallen over 27% during the past two reporting periods, to 41.1 million shares. That said, short interest still accounts for over 20% of the stock's float, or 11.2 times' TXMD's average daily volume.

 

Stop leaving money on the table with the same old broken options trading approach...

There is no options strategy that more perfectly capitalizes during earnings season better than this simple call and put buying strategy. Perfect for aggressive traders looking to recover their suffering portfolios so far in 2022. With the simplest possible options strategy, Schaeffer's team with 100+ years of options trading excellence, target 200% gains on every single trade. So many trades are being beaten down by the market, but don't be one of them! Don't waste another second... join us right now before the next trade is released! 

 
Schaeffer's Daily Bulletin Offer
 


 


 
Special Offers from Schaeffer's Trading Partners